May 21, 2013 -- Want to increase revenues in China? You might try lowering prices. It seems to have worked for GlaxoSmithKline. In 2009, the company reduced the cost of its allergy treatment, Avamys nasal spray. The number of units sold jumped to five times their previous figures, though revenues clearly gained less than that. Overall, GSK’s China revenues were up 20% in 2012, reaching $1.5 billion. More details....